INVESTORS RIGHTS AGREEMENT By and Between SK GLOBAL CHEMICAL CO., LTD. LOOP INDUSTRIES, INC., AND DANIEL SOLOMITA Dated as of July 29, 2021
Exhibit 4.1
By and Between
SK GLOBAL CHEMICAL CO., LTD.
AND
XXXXXX XXXXXXXX
Dated as of July 29, 2021
TABLE OF CONTENTS
1
|
Definitions
|
3
|
2
|
Registration
Rights
|
9
|
2.1
|
Required
Registration
|
9
|
2.2
|
Revocation
of Required Registration
|
9
|
2.3
|
Continuous
Effectiveness of Registration Statement
|
9
|
2.4
|
Obligations
of the Company
|
10
|
2.5
|
Information;
Investor Covenants
|
12
|
2.6
|
Expenses
|
12
|
2.7
|
Indemnification
|
12
|
2.8
|
SEC
Reports
|
15
|
2.9
|
Legend
Removal
|
15
|
3
|
Restrictions
on Beneficial Ownership
|
16
|
3.1
|
Standstill
|
16
|
4
|
Restrictions
on Dispositions
|
17
|
4.1
|
Lock-Up
|
17
|
4.2
|
Certain
Dispositions During Lock-Up
|
18
|
4.3
|
Certain
Dispositions and Indirect Transfers
|
18
|
4.4
|
Effect
of Prohibited Disposition
|
18
|
4.5
|
Compliance
with Laws
|
19
|
4.6
|
Legends
|
19
|
4.7
|
Offering
Lock-Up
|
19
|
5
|
Voting
Agreement
|
19
|
5.1
|
Voting
of Shares held by Founder
|
19
|
5.2
|
Founder
Covenant
|
20
|
6
|
Board
Composition
|
20
|
7
|
Subscription
Right.
|
22
|
8
|
Miscellaneous
|
23
|
8.1
|
Governing
Law; Submission to Jurisdiction
|
23
|
8.2
|
Dispute
Resolution
|
23
|
8.3
|
Waiver
|
24
|
8.4
|
Notices
|
24
|
8.5
|
Entire
Agreement
|
24
|
8.6
|
Amendments
|
24
|
8.7
|
Interpretation
|
24
|
8.8
|
Severability
|
25
|
8.9
|
Assignment
|
25
|
i
8.10
|
Successors
and Assigns
|
26
|
8.11
|
Counterparts
|
26
|
8.12
|
Fees
and Expenses
|
26
|
8.13
|
Third
Party Beneficiaries.
|
26
|
8.14
|
Remedies
|
26
|
8.15
|
Specific
Performance
|
26
|
8.16
|
Confidentiality
|
27
|
8.17
|
Termination.
|
27
|
Exhibit
A – Notice Addresses
ii
THIS
INVESTORS RIGHTS AGREEMENT (this “Agreement”) is made as of July 29,
2021, by and among SK global chemical Co., Ltd., a company
incorporated and existing under the laws of the Republic of Korea
with its principal offices at 00, Xxxx-xx, Xxxxxx-xx, Xxxxx, Xxxxx
00000 (the “Investor”), Loop Industries, Inc.,
a company incorporated and existing under the laws of the State of
Nevada with its principal offices at 000 Xxxxxxx-Xxxxxxx
Xxxxxxxxxx, Xxxxxx, Xxxxxx X0X 0X0 (the “Company”), and Xxxxxx Xxxxxxxx,
solely in his individual capacity and for the purposes of
Section 5 (the
“Founder”).
WHEREAS, the
Securities Purchase Agreement, dated as of June 22, 2021, by and
between the Investor and the Company (the “Purchase Agreement”) provides for
the issuance and sale by the Company to the Investor, and the
purchase by the Investor, of a number of shares of the
Company’s common stock, par value $0.0001 per share (the
“Common Stock”)
and certain warrants for the purchase of shares of Common Stock
(the “Warrants”,
and together with the shares of Common Stock purchased under the
Purchase Agreement (the “Purchased Shares”) and the shares
of Common Stock issued upon exercise of the Warrants (the
“Warrant
Shares”), the “Purchased Securities”);
and
WHEREAS, as a
condition to consummating the transactions contemplated by the
Purchase Agreement, the Investor, the Company and the Founder have
agreed upon certain rights and restrictions as set forth herein
with respect to the Purchased Securities and other securities of
the Company beneficially owned by the Investor and its Affiliates,
and it is a condition to the closing of the transactions
contemplated by the Purchase Agreement that this Agreement be
executed and delivered by the Investor and the
Company.
NOW,
THEREFORE, in consideration of the premises and mutual agreements
hereinafter set forth, and for other valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the
parties hereto agree as follows:
1. Definitions. As used in this
Agreement, the following terms shall have the following
meanings:
(a)
“Acquisition
Proposal” shall have the meaning set forth in
Section
3.1(d).
(b)
“Additional Subscription
Shares” shall have the meaning set forth in
Section
7.1.
(c)
“Affiliate”
shall mean, with respect to any Person, another Person that
controls, is controlled by or is under common control with such
Person. A Person shall be deemed to control another Person if such
Person possesses, directly or indirectly, the power to direct or
cause the direction of the management and policies of such Person,
whether through the ownership of voting securities, by contract or
otherwise. For the purposes of this Agreement, in no event shall
(i) the Investor or any of its Affiliates be deemed Affiliates of
the Company or any of its Affiliates, (ii) the Company or any of
its Affiliates be deemed Affiliates of the Investor or any of its
Affiliates or (iii) the Joint Venture or any other Person formed
pursuant to the Joint Venture Transaction Agreements be deemed an
Affiliate of either the Company or the Investor.
3
(d)
“Agreement”
shall have the meaning set forth in the Preamble, including all
Exhibits attached hereto.
(e)
“Arbitration”
shall have the meaning set forth in Section 8.2.
(f)
“Award” shall
have the meaning set forth in Section 8.2.
(g)
“beneficial
owner,” “beneficially owns,”
“beneficial
ownership” and terms of similar import used in this
Agreement shall, with respect to a Person, have the meaning set
forth in Rule 13d-3 under the Exchange Act (i) assuming the full
conversion into, and exercise and exchange for, shares of Common
Stock of all Common Stock Equivalents beneficially owned by such
Person and (ii) determined without regard for the number of days
within which such Person has the right to acquire such beneficial
ownership.
(h)
“Board” shall
mean the Board of Directors of the Company.
(i)
“Business
Combination” shall have the meaning set forth in
Section
3.1(g).
(j)
“Business Day”
shall mean a day on which commercial banking institutions in
Montreal, Québec, New York, New York and Seoul, the Republic
of Korea are open for business.
(k)
“Change of
Control” shall mean, with respect to the Company, any
of the following events: (i) any Person is or becomes the
beneficial owner (except that a Person shall be deemed to have
beneficial ownership of all shares that any such Person has the
right to acquire, whether such right which may be exercised
immediately or only after the passage of time), directly or
indirectly, of a majority of the total voting power represented by
all shares of Common Stock and any other voting securities of the
Company then issued and outstanding; (ii) the Company consolidates
with or merges into another corporation or entity, or any
corporation or entity consolidates with or merges into the Company,
other than (A) a merger or consolidation which would result in the
voting securities of the Company outstanding immediately prior to
such merger or consolidation continuing to represent (either by
remaining outstanding or by being converted into voting securities
of the surviving entity or any parent thereof) a majority of the
combined voting power of the voting securities of the Company or
such surviving entity or any parent thereof outstanding immediately
after such merger or consolidation, or (B) a merger or
consolidation effected to implement a recapitalization of the
Company (or similar transaction) in which no Person becomes the
beneficial owner, directly or indirectly, of a majority of the
total voting power of all shares of Common Stock and any other
voting securities of the Company then issued and outstanding or
(iii) the Company conveys, transfers or leases all or substantially
all of its assets to any Person other than a wholly-owned Affiliate
of the Company.
(l)
“Closing Date”
shall have the meaning set forth in the Purchase
Agreement.
(m)
“Common Stock”
shall have the meaning set forth in the Preamble.
4
(n)
“Common Stock
Equivalents” shall mean any options, warrants or other
securities or rights convertible into or exercisable or
exchangeable for, whether directly or following conversion into or
exercise or exchange for other options, warrants or other
securities or rights, shares of Common Stock.
(o)
“Company” shall
have the meaning set forth in the Preamble.
(p)
“Competitor”
shall mean any Person that, directly or indirectly, through one or
more of its Affiliates, (i) engages in a business that is engaged
in commercializing rDMT/rMEG products or manufacturing technology
based on methanolysis below 150 degrees Celsius or (ii) owns a
controlling equity interest in any Person described under clause
(i) hereof, in each case, as determined by the Board (excluding the
Investor Designee, if any) acting in good faith.
(q)
“Derivative”
shall have the meaning set forth in Section 3.1(a).
(r)
“Director
Conditions” shall have the meaning set forth in
Section
6(b).
(s)
“Director
Period” shall mean the period commencing on the
Closing Date and ending on the earlier to occur of (i) the date on
which the Investor and its Affiliates beneficially own less than
4,000,000 shares of Common Stock and (ii) the date on which the
Investor and its Affiliates beneficially own (without regard to any
Common Stock Equivalents beneficially owned by such Persons) less
than five percent (5.0%) of the shares of Common Stock then issued
and outstanding.
(t)
“Disposition” or
“Dispose of”
shall mean any (i) offer, sale, contract to sell, sale of any
option or contract to purchase, purchase of any option or contract
to sell, grant of any option, right or warrant for the sale of, or
other disposition of or transfer of any shares of Common Stock, or
any Common Stock Equivalents, including, without limitation, any
“short sale” or similar arrangement, or (ii) hedge,
swap or any other agreement or transaction that transfers, in whole
or in part, directly or indirectly, any of the economic consequence
of ownership of shares of Common Stock, whether any such hedge,
swap, agreement or transaction is to be settled by delivery of
Common Stock, other securities, in cash or otherwise.
(u)
“Dispute” shall
have the meaning set forth in Section 8.2.
(v)
“Exchange Act”
shall mean the Securities Exchange Act of 1934, as amended, and the
rules and regulations of the SEC promulgated
thereunder.
(w)
“Founder” shall
have the meaning set forth in the Preamble.
(x)
“Founder Shares”
shall have the meaning set forth in Section 5.1(a).
(y)
“Free Writing
Prospectus” shall have the meaning set forth in
Section
2.4(c).
5
(z)
“fully-diluted
ownership” shall have the meaning set forth in
Section 7.1.
(aa)
“Governmental
Authority” shall mean any court, agency, authority,
department, regulatory body or other instrumentality of any
government or country or of any national, federal, state,
provincial, regional, county, city or other political subdivision
of any such government or country or any supranational organization
of which any such country is a member.
(bb)
“ICC Arbitration
Rules” shall have the meaning set forth in
Section
8.2.
(cc)
“Indirect
Transfer” or “Indirectly Transfer” means any
transfer, sale or other disposition of any equity interests in the
Investor or any Affiliate of the Investor that, directly or
indirectly, controls the Investor (other than SK global chemical
Co., Ltd. or any such Affiliate that is a Person whose equity
interests are listed on a stock market or stock exchange or an
investment fund).
(dd)
“Investor” shall
have the meaning set forth in the Preamble.
(ee)
“Investor Affiliate
Assignee” shall have the meaning set forth in
Section 8.9.
(ff)
“Investor Affiliate Assignee
Joinder” shall have the meaning set forth in
Section 8.9.
(gg)
“Investor Affiliate Assignee
Parent” shall have the meaning set forth in
Section 8.9.
(hh)
“Investor Affiliate
Holder” shall have the meaning set forth in
Section 8.16.
(ii)
“Investor
Designee” shall have the meaning set forth in
Section
6(a).
(jj)
“Investor Permitted
Assignment” shall have the meaning set forth in
Section 8.9.
(kk)
“Joint Venture”
shall have the meaning set forth in the Purchase
Agreement.
(ll)
“Joint Venture Negotiation
Period” shall have the meaning set forth in the
Purchase Agreement.
(mm)
“Joint Venture Transaction
Agreements” shall have the meaning set forth in the
Purchase Agreement.
(nn)
“Law” or
“Laws” shall
mean all laws, statutes, rules, regulations, orders, judgments,
injunctions and/or ordinances of any Governmental
Authority.
6
(oo)
“Lock-Up Term”
shall have the meaning set forth in Section 4.1(a).
(pp)
“Modified
Clause” shall have the meaning set forth in
Section
8.8.
(qq)
“New Securities”
shall mean any shares of Common Stock or Common Stock Equivalents,
except for (a) shares of Common Stock or Common Stock Equivalents
that may be issued to employees or directors of, or advisors or
consultants to, the Company pursuant to an employee incentive
equity program of the Company or other agreement or arrangement as
approved by the Board, (b) shares of Common Stock or Common Stock
Equivalents issued as a dividend or other distribution on
outstanding securities of the Company; (c) shares of Common Stock
or Common Stock Equivalents that are issued by reason of a stock
split, split-up or other reorganization or recapitalization of the
Company; (d) shares of Common Stock or Common Stock Equivalents
issued upon the exercise or conversion of Common Stock Equivalents;
(e) shares of Common Stock or Common Stock Equivalents issued as
acquisition consideration pursuant to the acquisition of another
Person by the Company by merger, purchase of substantially all of
the assets or other reorganization or to a joint venture agreement
(provided that
shares of Common Stock or Common Stock Equivalents issued in a
Qualified Acquisition Issuance shall be deemed New Securities), (f)
Additional Subscription Shares and (g) warrants issued pursuant to
that certain Loan Offer, dated July 24, 2019, by and among
Investissement Québec, the Company and Loop Canada Inc., as
amended, supplemented or otherwise modified from time to
time.
(rr)
“New Securities
Issuance” shall have the meaning set forth in
Section
7.1.
(ss)
“Offering Lock-Up
Term” shall have the meaning set forth in Section 4.7.
(tt)
“Offeror” shall
have the meaning set forth in Section 3.1(d).
(uu)
“Permitted
Purchases” shall mean purchases of Common Stock by the
Investor and/or, subject to compliance with Section 4.1, its Affiliates, to
the extent necessary to reverse any decrease in the aggregate
percentage of the issued and outstanding shares of Common Stock
beneficially owned by the Investor and its Affiliates that results
solely from a net increase in the number of issued and outstanding
shares of Common Stock.
(vv)
“Person” shall
mean any individual, partnership, firm, corporation, association,
trust, unincorporated organization, government or any department or
agency thereof or other entity, as well as any syndicate or group
that would be deemed to be a Person under Section 13(d)(3) of the
Exchange Act.
(ww)
“Purchase
Agreement” shall have the meaning set forth in the
Preamble, and shall include all Exhibits attached
thereto.
(xx)
“Purchased
Securities” shall have the meaning set forth in the
Preamble, and shall be adjusted for (i) any stock split, stock
dividend, share exchange, merger, consolidation or similar
recapitalization and (ii) any Common Stock issued as (or issuable
upon the exercise of any warrant, right or other security that is
issued as) a dividend or other distribution with respect to, or in
exchange or in replacement of, the Purchased
Securities.
7
(yy)
“Purchased
Shares” shall have the meaning set forth in the
Preamble.
(zz)
“Qualified Acquisition
Issuance” shall have the meaning set forth in
Section 7.1.
(aaa)
“registers,”
“registered,”
and “registration” refer to a
registration effected by preparing and filing a Registration
Statement or similar document in compliance with the Securities
Act, and the declaration or ordering of effectiveness of such
Registration Statement or document by the SEC.
(bbb)
“Registrable
Securities” shall mean (i) the Purchased Shares and
the Warrant Shares, together with any shares of Common Stock issued
in respect thereof as a result of any stock split, stock dividend,
share exchange, merger, consolidation or similar recapitalization,
(ii) any shares of Common Stock purchased in Permitted Purchases,
(iii) any Additional Subscription Shares and (iv) any Common Stock
issued as (or issuable upon the exercise of any warrant, right or
other security that is issued as) a dividend or other distribution
with respect to, or in exchange or in replacement of, the shares of
Common Stock described in clauses (i), (ii) and (iii) of this
definition, provided, however, that shares of Common
Stock shall cease to be Registrable Securities when either (A) such
shares have been disposed of in accordance with the Registration
Statement, or (B) such shares may be sold under Rule 144 of the
Securities Act without any limitation as to time, volume or manner
of sale and without the need for the Company to comply with the
current public information requirement under Rule 144(c)(1) of the
Securities Act.
(ccc)
“Registration
Statement” shall have the meaning set forth in
Section
2.1.
(ddd)
“Representatives” shall mean, with
respect to any Person, its officers, directors, principals,
partners, managers, members, employees, consultants, agents,
financial advisors, investment bankers, attorneys, accountants,
potential debt and equity financing sources (excluding any
co-investors), and other representatives.
(eee)
“Required
Approvals” shall have the meaning set forth in
Section
5.1.
(fff)
“Required
Period” shall have the meaning set forth in
Section
2.3.
(ggg)
“Required
Registration” shall have the meaning set forth in
Section
2.1.
(hhh)
“SEC” shall mean
the United States Securities and Exchange Commission.
(iii)
“Securities Act”
shall mean the Securities Act of 1933, as amended, and the rules
and regulations of the SEC promulgated thereunder.
(jjj)
“Standstill
Term” shall have the meaning set forth in Section 3.1.
8
(kkk)
“Subscription
Notice” shall have the meaning set forth in
Section
7.2.
(lll)
“Subscription
Right” shall have the meaning set forth in
Section
7.1.
(mmm) “Third Party” shall mean any Person
other than the Investor or any of its Affiliates.
(nnn)
“Trading Day”
shall mean a day on which the relevant Trading Market is open for
trading.
(ooo)
“Trading Market”
shall mean any of the following markets or exchanges on which the
Common Stock is listed or quoted for trading on the date in
question: the NYSE American, the Nasdaq Capital Market, the Nasdaq
Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the
foregoing).
(ppp)
“Tribunal” shall
have the meaning set forth in Section 8.2.
(qqq)
“Violation”
shall have the meaning set forth in Section 2.7(a).
(rrr)
“Volume-Weighted Average
Closing Price” shall mean, for any period of Trading
Days, the volume-weighted (based on the number of shares of Common
Stock traded on each day that the closing price is used for this
calculation) average of the closing sale price per share of the
Common Stock on the relevant Trading Market during such
period.
(sss)
“Warrant Shares”
shall have the meaning set forth in the Preamble.
(ttt)
“Warrants” shall
have the meaning set forth in the Preamble.
2. Registration
Rights.
2.1
Required
Registration. As soon as practicable, but in any event
within 90 days after the expiration of the Lock-Up Term, the
Company shall prepare and file with the SEC a Registration
Statement on Form S-3 covering the resale of the Registrable
Securities as a secondary offering to be made on a continuous basis
pursuant to Rule 415 (the “Required Registration”). The
applicable Registration Statement (including any preliminary or
final prospectus or prospectus supplement contained therein) is
referred to herein as the “Registration
Statement.”
2.2
Revocation of Required
Registration. With respect to the Required Registration, the
Investor may, at any time prior to the effective date of such
Registration Statement, waive the requirement to have all or any of
the Registrable Securities owned by the Investor included therein
by providing a written notice to the Company, in which case such
Registrable Securities will not be included in such Registration
Statement.
2.3
Continuous Effectiveness
of Registration Statement. The Company will use its
commercially reasonable efforts to cause the Registration Statement
filed pursuant to this Section 2 to be declared
effective by the SEC or to become effective under the Securities
Act as promptly as practicable and to keep such Registration
Statement that has been declared or becomes effective continuously
effective until the Investor no longer holds any Registrable
Securities or unexercised Warrants (the “Required Period”).
9
2.4
Obligations of the
Company. In connection with the Registration Statement and
during the Required Period, the Company shall:
(a)
prepare and file with the SEC a Registration Statement with respect
to the Registrable Securities; provided that at least ten (10)
Business Days prior to filing the Registration Statement or any
prospectus or any amendments or supplements thereto, the Company
shall furnish to the Investor and its counsel copies of all such
documents proposed to be filed, and the Investor shall have the
opportunity to comment on any information that is contained therein
and the Company shall consider all such comments in good faith and
shall make the corrections reasonably requested by the Investor
with respect to any information pertaining solely to the Investor
and the plan of distribution prior to filing the Registration
Statement or other documents;
(b)
prepare and file with the SEC such amendments, including
post-effective amendments to the Registration Statement and/or
replacement shelf registration statements and supplements to the
Registration Statement and any prospectus used in connection
therewith as may be necessary to keep the Registration Statement
effective for the Required Period, and cause the prospectus to be
supplemented by any required prospectus supplement, and as so
supplemented to be filed pursuant to Rule 424 under the Securities
Act, to comply with the provisions of the Securities Act with
respect to the disposition of all Registrable Securities covered by
such Registration Statement for the Required Period; provided that at least ten (10)
Business Days prior to filing any such amendments and
post-effective amendments or supplements thereto, the Company shall
furnish to the Investor and its counsel copies of all such
documents proposed to be filed, and promptly incorporate into a
Registration Statement, prospectus supplement or post-effective
amendment such information as the Investor reasonably requests
should be included therein relating to the plan of distribution
with respect to such Registrable Securities; and make all required
filings of such prospectus supplement or post-effective amendment
as soon as reasonably practicable after being notified of the
matters to be incorporated in such prospectus supplement or
post-effective amendment;
(c)
furnish to the Investor such numbers of conformed copies of such
Registration Statement, and of each amendment and supplement
thereto, such number of copies of the prospectus contained in or
deemed part of such Registration Statement (including each
preliminary prospectus and any summary prospectus) and each free
writing prospectus (as defined in Rule 405 of the Securities Act)
(a “Free Writing
Prospectus”) utilized in connection therewith and any
other prospectus filed under Rule 424 under the Securities Act in
conformity with the requirements of the Securities Act, and such
other documents as they may reasonably request in order to
facilitate the public sale or other disposition of the Registrable
Securities;
(d)
notify the Investor promptly of the filing of the Registration
Statement, any amendment thereto, the prospectus or any prospectus
supplement related thereto or post-effective to the Registration
Statement and/or replacement shelf registration statement or any
Free Writing Prospectus utilized in connection
therewith;
(e)
notify the Investor, promptly after the Company shall receive
notice thereof, of the time when the Registration Statement becomes
or is declared effective or when any amendment or supplement or any
prospectus forming a part of such Registration Statement has been
filed;
10
(f)
notify the Investor promptly of any comment letter from the SEC or
any request by the SEC or any other U.S. or state Governmental
Authority for the amending or supplementing of the Registration
Statement or prospectus or for additional information and promptly
deliver to the Investor copies of any comments received from the
SEC and any correspondence from and to the SEC and respond as
promptly as reasonably practicable to such comments;
(g)
notify the Investor promptly of any stop order suspending the
effectiveness of the Registration Statement or prospectus or the
initiation of any proceedings for that purpose, and use all
reasonable efforts to obtain the withdrawal of any such order or
the termination of such proceedings;
(h)
use all reasonable efforts to register and qualify the Registrable
Securities covered by the Registration Statement under such other
securities or blue sky Laws of such jurisdictions as shall be
reasonably requested by the Investor, use all reasonable efforts to
keep each such registration or qualification effective, including
through new filings, or amendments or renewals, during the Required
Period, and notify the Investor of the receipt of any written
notification with respect to any suspension of any such
qualification or the lifting of any suspension of the qualification
(or exemption from qualification) of any of the Registrable
Securities for sale in any jurisdiction at the earliest reasonable
practicable date; provided, however, that the Company shall
not be required in connection therewith or as a condition thereto
to qualify to do business or to file a general consent to service
of process in any such states or jurisdictions, except as may be
required by the Securities Act;
(i)
promptly notify the Investor at any time when a prospectus relating
thereto is required to be delivered under the Securities Act of the
happening of any event as a result of which the prospectus included
in the Registration Statement or any offering memorandum or other
offering document includes an untrue statement of a material fact
or omits to state any material fact required to be stated therein
or necessary to make the statements therein not misleading in the
light of the circumstances then existing, and promptly prepare a
supplement or amendment to such prospectus or file any other
required document so that, as thereafter delivered to the
purchasers of such Registrable Securities, such prospectus will not
contain an untrue statement of material fact or omit to state any
fact necessary to make the statements therein not
misleading;
(j)
use all reasonable efforts to comply with all applicable rules and
regulations of the SEC relating to such registration and make
generally available to its security holders earning statements
satisfying the provisions of Section 11(a) of the Securities Act,
provided that the
Company will be deemed to have complied with this Section 2.4(j) with respect to
such earning statements if it has satisfied the provisions of Rule
158 promulgated under the Securities Act;
(k)
maintain a transfer agent and registrar for all Registrable
Securities covered by such Registration Statement from and after a
date no later than the effective date of such Registration
Statement;
11
(l)
notify the Investor promptly upon the happening of any event that
makes any statement made in such Registration Statement or related
prospectus or any document incorporated or deemed to be
incorporated therein by reference untrue in any material respect or
that requires the making of any changes in such Registration
Statement, prospectus or documents so that, in the case of the
Registration Statement, it will not contain an untrue statement of
a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein not
misleading, and that in the case of the prospectus, it will not
contain an untrue statement of a material fact or omit to state a
material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not
misleading; provided that such notice need
not include the nature or details concerning such
event;
(m)
if requested by counsel to the Investor, (i) promptly incorporate
in a prospectus supplement or post-effective amendment to the
Registration Statement such information as the Company reasonably
agrees (upon advice of counsel) is required to be included therein
and (ii) make all required filings of such prospectus supplement or
such post-effective amendment promptly after the Company has
received notification of the matters to be incorporated in such
prospectus supplement or post-effective amendment and has agreed to
their inclusion in the Registration Statement; and
(n)
cause the Registrable Securities covered by such Registration
Statement to be listed on each securities exchange, if any, on
which equity securities issued by the Company are then
listed.
2.5
Information; Investor
Covenants. It shall be a condition precedent to the
obligations of the Company to take any reasonable action pursuant
to this Section 2
with respect to the Registrable Securities that the Investor
furnish to the Company such information regarding itself and the
Registrable Securities held by it as is required by Regulation S-K
Item 507 or as shall be necessary to effect the registration of the
Registrable Securities. The Investor agrees that, upon receipt of
any notice from the Company of the happening of an event pursuant
to Section 2.4(i)
hereof, the Investor will immediately discontinue disposition of
Registrable Securities pursuant to any Registration Statement
covering such Registrable Securities, until the Investor is advised
by the Company that such dispositions may again be made. The
Investor covenants and agrees that it will comply with the
prospectus delivery requirements of the Securities Act as
applicable to it or an exemption therefrom in connection with sales
of Registrable Securities pursuant to any Registration
Statement.
2.6
Expenses. The
Company will pay all expenses associated with the preparation and
filing of a Registration Statement, including, without limitation,
filing fees, the Company’s counsel and accounting fees and
expenses, costs associated with clearing the Registrable Securities
for sale under applicable state securities Laws and listing fees.
In no event shall the Company be responsible for any discounts,
commissions, fees and expenses of the Investor’s counsel,
underwriters, selling brokers, dealer managers or similar
securities industry professionals with respect to the Registrable
Securities being sold.
2.7
Indemnification. In
the event any Registrable Securities are included in a Registration
Statement under this Agreement:
12
(a)
The Company shall indemnify and hold harmless the Investor, any
underwriter (as defined in the Securities Act) for the Investor and
each Person, if any, who controls the Investor or underwriter
within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act and the officers, directors, owners, agents
and employees of such controlling Persons, against any and all
losses, claims, damages or liabilities (joint or several) to which
they may become subject under any securities Laws including,
without limitation, the Securities Act, the Exchange Act, or any
other statute or common law of the United States or any other
country or political subdivision thereof, or otherwise, including
the amount paid in settlement of any litigation commenced or
threatened (including any amounts paid pursuant to or in settlement
of claims made under the indemnification or contribution provisions
of any underwriting or similar agreement entered into by the
Investor in connection with any offering or sale of securities
covered by this Agreement), and shall promptly reimburse them, as
and when incurred, for any legal or other expenses incurred by them
in connection with investigating any claims and defending any
actions, insofar as any such losses, claims, damages or liabilities
(or actions in respect thereof) arise out of or are based upon any
of the following statements, omissions or violations (each, a
“Violation”):
(i) any untrue statement or alleged untrue statement of a material
fact contained in or incorporated by reference into such
Registration Statement, including any preliminary prospectus or
final prospectus contained therein or any free writing prospectus
or any amendments or supplements thereto, or in any offering
memorandum or other offering document relating to the offering and
sale of such securities, (ii) the omission or alleged omission to
state therein a material fact required to be stated therein, or
necessary to make the statements therein not misleading or (iii)
any violation or alleged violation by the Company (or any of its
agents or Affiliates) of the Securities Act, the Exchange Act, any
state securities Law, or any rule or regulation promulgated under
any state securities Law, in each case arising from such
Registration Statement; provided, however, the Company shall not
be liable in any such case for any such loss, claim, damage,
liability or action to the extent that it (A) arises out of or is
based upon a Violation which occurs solely in reliance upon and in
conformity with written information furnished expressly for use in
connection with such registration by the Investor; or (B) is caused
by the Investor’s disposition of Registrable Securities after
notice from the Company pursuant to Section 2.4(g) during any
period during which the Investor is obligated to discontinue any
disposition of Registrable Securities as a result of any stop order
suspending the effectiveness of any Registration Statement or
prospectus with respect to Registrable Securities. The Company
shall pay, as incurred, any legal or other expenses reasonably
incurred by any Person intended to be indemnified pursuant to this
Section 2.7(a), in
connection with investigating or defending any such loss, claim,
damage, liability or action; provided, however, that the indemnity
agreement contained in this Section 2.7(a) shall not apply
to amounts paid in settlement of any such loss, claim, damage,
liability or action if such settlement is effected without consent
of the Company, which consent shall not be unreasonably withheld,
conditioned or delayed.
13
(b)
The Investor shall indemnify and hold harmless the Company, each of
its directors, each of its officers who has signed the Registration
Statement, each Person, if any, who controls the Company within the
meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act and the officers, directors, owners, agents and
employees of such controlling Persons, any underwriter, any other
Investor selling securities in such Registration Statement and any
controlling Person of any such underwriter or other Investor,
against any losses, claims, damages or liabilities (joint or
several) to which any of the foregoing Persons may become subject,
under liabilities (or actions in respect thereto) which arise out
of or are based upon any Violation, in each case to the extent (and
only to the extent) that such Violation: (i) arises out of or is
based upon a Violation which occurs solely in reliance upon and in
conformity with written information furnished expressly for use in
connection with such registration by the Investor; or (ii) is
caused by the Investor’s disposition of Registrable
Securities after notice from the Company pursuant to Section 2.4(g) during any
period during which the Investor is obligated to discontinue any
disposition of Registrable Securities as a result of any stop order
suspending the effectiveness of any Registration Statement or
prospectus with respect to Registrable Securities. The Investor
shall pay, as incurred, any legal or other expenses reasonably
incurred by any Person intended to be indemnified pursuant to this
Section 2.7(b), in
connection with investigating or defending any such loss, claim,
damage, liability or action; provided, however, that the indemnity
agreement contained in this Section 2.7(b) shall not apply
to amounts paid in settlement of any such loss, claim, damage,
liability or action if such settlement is effected without consent
of the Investor, which consent shall not be unreasonably
withheld.
(c)
Promptly after receipt by an indemnified party under this
Section 2.7 of
notice of the commencement of any action (including any action by a
Governmental Authority), such indemnified party shall, if a claim
in respect thereof is to be made against any indemnifying party
under this Section
2.7, deliver to the indemnifying party a written notice of
the commencement thereof and the indemnifying party shall have the
right to participate in, and, to the extent the indemnifying party
so desires, jointly with any other indemnifying party similarly
noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified
party shall have the right to retain its own counsel, with the
reasonable fees and expenses to be paid by the indemnifying party,
if representation of such indemnified party by the counsel retained
by the indemnifying party would be inappropriate due to actual or
potential differing interests between such indemnified party and
any other party represented by such counsel in such proceeding. The
failure to deliver written notice to the indemnifying party within
a reasonable time of the commencement of any such action, if
prejudicial in a material respect to its ability to defend such
action, shall relieve such indemnifying party of any liability to
the indemnified party under this Section 2.7, but the omission
so to deliver written notice to the indemnifying party shall not
relieve it of any liability that it may have to any indemnified
party otherwise than under this Section 2.7.
14
(d)
In order to provide for just and equitable contribution to joint
liability in any case in which a claim for indemnification is made
pursuant to this Section
2.7 but it is judicially determined (by the entry of a final
judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of
appeal) that such indemnification may not be enforced in such case
notwithstanding the fact that this Section 2.7 provided for
indemnification in such case, the Company and the Investor shall
contribute to the aggregate losses, claims, damages or liabilities
to which they may be subject (after contribution from others) in
proportion to the relative fault of the Company, on the one hand,
and the Investor, on the other hand; provided, however, that in any such case,
no Person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) shall be entitled
to contribution from any Person who was not guilty of such
fraudulent misrepresentation; provided further, however, that in no event shall
any contribution under this Section 2.7(d) on the part of
any Investor exceed the net proceeds received by the Investor from
the sale of Registrable Securities giving rise to such contribution
obligation, except in the case of fraud or willful misconduct by
the Investor.
(e)
The obligations of the Company and the Investor under this
Section 2.7 shall
survive the completion of any offering of Registrable Securities in
a Registration Statement under this Agreement and
otherwise.
2.8
SEC Reports. With a
view to making available to the Investor the benefits of Rule 144
under the Securities Act and any other rule or regulation of the
SEC that may at any time permit the Investor to sell Registrable
Securities of the Company to the public without registration, the
Company agrees to at any time that it is a reporting company under
Section 13 or 15(d) of the Exchange Act:
(a)
file with the SEC in a timely manner all reports and other
documents required of the Company under the Exchange Act;
and
(b)
furnish to the Investor, so long as the Investor owns any
Registrable Securities, forthwith upon request (i) a written
statement by the Company that it has complied with the reporting
requirements of the Exchange Act, (ii) a copy of the most recent
annual or quarterly report of the Company and such other reports
and documents so filed by the Company, and (iii) such other
information as may be reasonably requested in availing the Investor
of any rule or regulation of the SEC (exclusive of Rule 144A) which
permits the selling of any Registrable Securities without
registration.
2.9
Legend Removal.
After the expiration of the Lock-Up Term and provided that such
transfer is being made in compliance with this Agreement, the
Company shall cause the legends set forth in Section 4.6 to be removed from
the Purchased Securities, no later than two (2) Business Days from
receipt of a written request from the Investor pursuant to this
Section 2.9, to the
extent (a) such Purchased Securities have been resold under an
effective Registration Statement, (b) such Purchased Securities
have been or will be transferred in compliance with Rule 144 under
the Securities Act, (c) such Purchased Securities are eligible for
resale pursuant to Rule 144(b)(1)(i) under the Securities Act
without the requirement for the Company to be in compliance with
the current public information required under Rule 144(c)(1) under
the Securities Act as to such shares and without volume or
manner-of-sale restrictions or (d) the Investor shall have provided
the Company with an opinion of counsel, reasonably satisfactory to
the Company, stating that such Purchased Securities may lawfully be
transferred without registration under the Securities
Act.
15
3. Restrictions on Beneficial
Ownership.
3.1
Standstill. During
the period (such period, the “Standstill Term”) commencing as of
the Closing Date and continuing until the later of (A) the date
that concludes any 90 day continuous period during which no
Investor Designee serves on the Board, provided that, notwithstanding
the foregoing, if the Investor subsequently designates a new
Investor Designee that serves on the Board following such 90-day
period, the Standstill Term shall be reinstated commencing as of
such date that such new Investor Designee serves on the Board, and
(B) the date on which the Investor and its Affiliates beneficially
own less than five percent (5.0%) of the shares of Common Stock
then issued and outstanding, neither the Investor nor any Investor
Affiliate Assignee Parent shall do any of the following, either
directly or indirectly by causing, requesting or directing its
Affiliates to do any of the following, except as expressly approved
or invited in writing by the Company:
(a)
other than Permitted Purchases and purchases of Additional
Subscription Shares, directly or indirectly, acquire beneficial
ownership of Common Stock and/or Common Stock Equivalents and/or
any instrument that gives the Investor or any of its Affiliates the
economic equivalent of ownership of an amount of securities of the
Company (a “Derivative”), except, nothing in
this Section 3.1(a)
shall prevent or prohibit the Investor or any of its Affiliates
from (i) investing in a fund with respect to which the Investor or
any of its Affiliates does not have or share decision-making
authority over investment or divestment decisions; or (ii) in the
case of an Affiliate that is a private equity fund or a credit
fund, investing through a portfolio company of such
fund;
(b)
make a tender, exchange or other public offer to acquire Common
Stock and/or Common Stock Equivalents;
(c)
directly or indirectly, (i) seek to have called any meeting of the
stockholders of the Company or propose any matter to be voted upon
by the stockholders of the Company, or (ii) propose or nominate for
election to the Board any person whose nomination has not been
approved by a majority of the Board (excluding the Investor
Designee, if any);
(d)
directly or indirectly, encourage, accept or support a tender,
exchange or other offer or proposal by any other Person or group
(an “Offeror”)
for securities of the Company (if such offer or proposal would, if
consummated, result in a Change of Control of the Company, such
offer or proposal is referred to as an “Acquisition Proposal”);
provided,
however, that from
and after the filing of a Schedule 14D-9 (or successor form of
Tender Offer Solicitation/Recommendation Statement under Rule 14d-9
of the Exchange Act) by the Company recommending that stockholders
accept any such offer filed after such offer has commenced, the
Investor shall not be prohibited from taking any of the actions
otherwise prohibited by this Section 3.1(d) for so long as
the Board maintains and does not withdraw such
recommendation;
(e)
directly or indirectly, solicit proxies or consents or propose or
seek or become a participant in a solicitation (as such terms are
defined in Regulation 14A under the Exchange Act), or seek to
advise or influence any Person, with respect to voting of any
securities of the Company;
16
(f)
deposit any securities of the Company in a voting trust or subject
any securities of the Company to any arrangement or agreement with
respect to the voting of such securities, including the granting of
any proxy;
(g)
propose (i) any merger, consolidation, business combination, tender
or exchange offer, purchase of the Company’s assets or
businesses, purchase of any securities of the Company or any
Derivative, or any similar transaction involving the Company or
(ii) any recapitalization, restructuring, liquidation or other
extraordinary transaction with respect to the Company, in each case
without the prior written consent of the Board (a transaction
described in clauses (i) and (ii) that would result in a Change of
Control, is referred to as a “Business
Combination”);
(h)
act in concert with any Third Party to take any action in clauses
(a) through (g) above, or, directly or indirectly, form, join or in
any way participate in a “partnership, limited partnership,
syndicate, or other group” as such terms are used in the
rules of the SEC with respect to the Company or any securities of
the Company;
(i)
request or propose to the Board or the Company (or any of its
officers, directors, Affiliates employees, attorneys, accountants,
financial advisors and other professional representatives),
directly or indirectly, any amendment or waiver of any provision of
this Section 3.1
(including this clause (i));
(j)
make any public announcement regarding, or take any action that
could require the Company to make a public announcement regarding,
a potential Business Combination or any of the matters set forth in
clauses (a) through (i) above; or
(k)
enter into discussions, negotiations, arrangements or agreements
with any Person relating to the foregoing actions referred to in
(a) through (i) above;
provided, however, that nothing contained
in this Section 3.1
shall prohibit the Investor or any of its Affiliates from making
confidential, nonpublic proposals to the Board for a transaction
involving a Business Combination following the public announcement
by the Company after the Closing Date that it has entered into a
definitive agreement with a Third Party for a transaction involving
a Business Combination, or the Investor Designee from performing
its duties as a member of the Board.
4. Restrictions on
Dispositions.
4.1
Lock-Up.
(a)
For the period commencing as of the Closing Date and continuing
until the date that is the second (2nd) anniversary of the Closing
Date (the “Lock-Up
Term”), the Investor shall not, and shall cause its
Affiliates not to, (x) Dispose of any of the Purchased Securities,
any shares of Common Stock purchased in Permitted Purchases,
Additional Subscription Shares, or any other shares of Common Stock
beneficially owned by them as of the date of this Agreement,
together with any shares of Common Stock issued in respect thereof
as a result of any stock split, stock dividend, share exchange,
merger, consolidation or similar recapitalization, or (y) Dispose
of any Common Stock issued as (or issuable upon the exercise of any
warrant, right or other security that is issued as) a dividend or
other distribution with respect to, or in exchange or in
replacement of, the shares of Common Stock described in clause (x)
of this sentence, in each case except (1) with the prior consent of
a majority of the Board (excluding the Investor Designee, if any)
which consent may be granted or withheld in the Board’s sole
discretion, or (2) as provided in Section 4.2 below; provided that such Lock-Up Term
shall terminate upon the earlier to occur of (i) a material breach
by the Company or Xxxxxx Xxxxxxxx of any of their obligations under
this Agreement, the Purchase Agreement or any of the Joint Venture
Transaction Agreements, provided, further, that the Investor has
notified the Company or Xxxxxx Xxxxxxxx (as applicable) of such
material breach in writing and, if such material breach is capable
of being cured, such material breach remains uncured for 30 days
after delivery of such notice, (ii) the expiration of the Joint
Venture Negotiation Period without the Joint Venture Transaction
Agreements having been executed or the determination by the
Investor, in its reasonable discretion, that the negotiations for
the Joint Venture Transaction Agreements are not continuing in good
faith, and (iii) the Joint Venture Transaction Agreements are
terminated.
17
4.2
Certain Dispositions
During Lock-Up.
(a)
Disposition in Tender
Offer. Notwithstanding Section 4.1, the Investor and
its Affiliates may, at any time, Dispose of any of the Purchased
Securities, any shares of Common Stock purchased in Permitted
Purchases, Additional Subscription Shares or any other shares of
Common Stock beneficially owned by them into (i) a tender offer by
a Third Party which is not opposed by the Board (but only after the
Company’s filing of a Schedule 14D-9, or any amendment
thereto, with the SEC disclosing the recommendation of the Board
with respect to such tender offer), unless Investor is then in
breach of its obligations pursuant to Section 3.1 with respect to the
tender offer or (ii) an issuer tender offer by the
Company.
(b)
Required
Disposition. Notwithstanding Section 4.1 but subject to
Section 4.3, the
Investor and its Affiliates may, at any time, Dispose of any of the
Purchased Securities, any shares of Common Stock purchased in
Permitted Purchases, Additional Subscription Shares or any other
shares of Common Stock beneficially owned by them to the extent the
Investor or its Affiliates is ordered or otherwise required to do
so by any Law or Governmental Authority. The Company shall use its
reasonable best efforts to cooperate with the Investor and its
Affiliates to facilitate any such Disposition described in this
Section
4.2(b).
4.3
Certain Dispositions and
Indirect Transfers. Notwithstanding Section 4.1, in no event shall
the Investor or any Investor Affiliate Assignee Parent do any of
the following, either directly or indirectly by causing, requesting
or directing their respective Affiliates to do any of the
following, at any time: Dispose of any Purchased Securities, any
shares of Common Stock purchased in Permitted Purchases, Additional
Subscription Shares or any other shares of Common Stock
beneficially owned by the Investor or any of its Affiliates to any
Competitor; provided, however, that the restrictions
set forth in this sentence shall not apply to any Disposition of
Purchased Securities or Common Stock in an unsolicited open market
transaction or a registered offering. Notwithstanding anything
herein to the contrary, following an Investor Permitted Assignment
and during the Lock-Up Term, the Investor and each Investor
Affiliate Assignee Parent shall not (and the Investor and each
Investor Affiliate Assignee Parent shall cause their respective
Affiliates not to), at any time, effect an Indirect Transfer unless
(a) the Indirect Transfer is to a Person that is not a Competitor,
and (b) after giving effect to such Indirect Transfer, (i) the
outstanding equity interests in the Investor are wholly-owned by
the Investor Affiliate Assignee Parents (together with their
respective wholly-owned Affiliates), and (ii) the Investor
Affiliate Assignee Parents (together with their respective
wholly-owned Affiliates) control the Investor to make decisions
with respect to its investment in the Company. The Investor shall
provide advance notice of each Indirect Transfer to the Company,
including the identity of each Person acquiring an interest in the
Investor or the relevant Affiliate. Notwithstanding anything herein
to the contrary, none of the foregoing shall prohibit or restrict
the transfer of shares or other securities of any entity that is
listed on xxx.xx.xxx/xxxxxxxxx (including the subsidiaries of such
entities other than any such subsidiary, all or substantially all
of the assets of which, consist of securities of the Company,
whether directly or indirectly held by such
subsidiary).
4.4
Effect of Prohibited
Disposition. If any Disposition or Indirect Transfer is made
or attempted contrary to the provisions of this Agreement, (a) such
purported Disposition or Indirect Transfer shall be void ab initio,
(b) the Company shall have, in addition to all other legal or
equitable remedies that it may have, the right to injunctive relief
and specific performance to enforce the provisions of this
Agreement, and (c) the Company shall have the right to refuse to
recognize any transferee in a Disposition as a stockholder for any
purpose.
18
4.5
Compliance with
Laws. Notwithstanding any other provision of this Article 4,
the Investor acknowledges and agrees that the Purchased Securities
and any Additional Subscription Shares may be disposed of only (1)
pursuant to an effective registration statement under, and in
compliance with the requirements of, the Securities Act, or (2)
pursuant to an available exemption from, or in a transaction not
subject to, the registration requirements of the Securities Act,
and in compliance with any applicable state and federal securities
Laws.
4.6
Legends. The
Purchased Securities and Additional Subscription Shares will bear
restrictive instructions in substantially the following form (and a
stop-transfer order may be placed against transfer of the book
entries for such Purchased Securities and Additional Subscription
Shares):
THE
SECURITIES REPRESENTED BY THIS BOOK ENTRY HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES
LAWS OF ANY STATE AND ARE SUBJECT TO THE INVESTORS RIGHTS
AGREEMENT, DATED JULY 29, 2021 AMONG THE COMPANY, XXXXXX XXXXXXXX,
AND SK GLOBAL CHEMICAL CO., LTD. THE SECURITIES MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED
EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN
AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS. IN THE
ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT, THE COMPANY SHALL
BE ENTITLED TO REQUIRE AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED
OR OTHER EVIDENCE OF EXEMPTION EXISTS.
4.7
Offering Lock-Up.
Until the date that concludes any 90 day continuous period during
which no Investor Designee serves on the Board (“Offering Lock-Up Term”),
provided that, if
the Investor subsequently designates a new Investor Designee that
serves on the Board following such 90-day period, the Offering
Lock-Up Term shall be reinstated commencing as of such date that
such new Investor Designee serves on the Board, the Investor shall,
if requested by the Company and an underwriter of an offering of
Common Stock or other securities of the Company, agree not to
Dispose of any Common Stock and/or Common Stock Equivalents for a
specified period of time, such period of time not to exceed
forty-five (45) days; provided that the foregoing
restriction shall apply only (a) if and to the extent that all
directors and executive officers of the Company and any stockholder
of the Company with a board seat are subject to the same
restriction for that underwritten offering by the Company and (b)
if the Company has notified the Investor of any such proposed
offering as soon as reasonably practicable. Such agreement shall be
in writing in a form satisfactory to the Company and the
underwriter(s) in such offering. The Company may impose stop
transfer instructions with respect to the shares of Common Stock
and/or Common Stock Equivalents subject to the foregoing
restrictions until the end of the specified period of
time.
5. Voting
Agreement.
5.1
Voting of Shares held by
Founder. The Founder agrees that, prior to the date hereof,
at any meeting of the shareholders of the Company, or any
adjournment or postponement thereof, or in connection with any
written consent of the shareholders of the Company, with respect to
any matter that needs to be approved by shareholders of the Company
to give effect to the Investor’s rights under this Agreement,
the Purchase Agreement, and the Warrants (the “Required Approvals”), the Founder
shall:
19
(a)
appear at such meeting or otherwise cause the shares of the Series
A Preferred Stock of the Company and the Common Stock for which the
Founder is the registered and/or direct or indirect beneficial
owner of, or exercises control or direction over (the
“Founder
Shares”) to be counted as present thereat for purposes
of calculating a quorum; and
(b)
vote (or cause to be voted), or deliver a proxy (or cause a proxy
to be delivered) covering all of the Founder Shares that the
Founder shall be entitled to so vote, provided that, in the case of
the Founder Shares that are shares of Series A Preferred Stock of
the Company, the Founder may, where applicable, deliver an action
by written consent with respect to such Founder Shares in lieu of
voting such Founder Shares at a meeting of the shareholders of the
Company, (i) in favor of the Required Approvals, and (ii) against
any proposal that conflicts with or would interfere with the
exercise of the Investor’s rights under this
Agreement.
5.2
Founder Covenant.
Prior to the termination of this Agreement, Founder agrees not to
enter into any agreement, arrangement or understanding (whether
written or oral, binding or non-binding) with any Person to vote,
act by written consent, or give instructions in any manner
inconsistent with Section 5.1. Any such vote
shall be cast, or consent shall be given, in accordance with such
procedures relating thereto so as to ensure that it is duly counted
for purposes of determining that a quorum is present and for
purposes of recording the results of such vote or
consent.
6. Board
Composition.
(a)
Subject to the terms of this Section 6, effective as of the
Closing Date, the Board will appoint a designee of the Investor
(the “Investor
Designee”), reasonably acceptable to the Board, as a
director of the Company for a term expiring at the Company’s
next annual meeting of stockholders or upon such Investor
Designee’s earlier death, disability, resignation or removal
(including removal by operation of Law). The Company and the
Investor agree that Xxxxxxxx Xxx shall be the initial Investor
Designee. The Company agrees that, during the Director Period, the
Board shall nominate the individual serving as such Investor
Designee (or any individual subsequently designated by the Investor
to serve as the Investor Designee) for election or re-election, as
the case may be, as a director at each subsequent meeting of the
Company’s stockholders at which directors are to be elected,
and use commercially reasonable efforts to cause the Investor
Designee to be elected or re-elected, including providing the same
level of support as is provided for other nominees. Upon the end of
the Director Period, the Investor shall cause the Investor Designee
to tender to the Board, as soon as practicable and in any event
within five (5) days following the end of the Director Period, his
or her resignation from the Board. During the Director Period, the
Company will not decrease the size of the Board if such decrease
would require the resignation of the Investor
Designee.
20
(b)
As a condition to any appointment or nomination for election to the
Board, each Investor Designee shall (i) meet the qualifications
required of all directors of the Company by the Company’s
Nominating and Corporate Governance Committee and those mandated by
applicable Law, (ii) agree, in writing, to be bound by the terms
and conditions of all of the Company’s policies applicable to
its directors, (iii) make such acknowledgements and enter into such
agreements as the Company requires of all directors, including,
without limitation, with respect to confidentiality, the
Company’s code of ethics, xxxxxxx xxxxxxx policy and Section
16 reporting procedures, and (iv) be able to dedicate sufficient
time and resources for the diligent performance of the duties
required of a member of the Board (the “Director Conditions”). Without
limiting the foregoing, each proposed Investor Designee shall be
subject to satisfaction of the criteria for Board membership
established by the Nominating and Corporate Governance Committee of
the Board, including the director qualification criteria thereof,
as determined in the reasonable and good faith discretion of the
Nominating and Corporate Governance Committee of the Board and the
Board in the same manner as the Nominating and Corporate Governance
Committee of the Board and the Board would consider any candidate
for Board membership. The Board or the Nominating and Corporate
Governance Committee of the Board will evaluate the Investor
Designee for potential roles on the committees of the Board,
consistent with evaluations of other directors for such positions
and subject to applicable Law and the listing rules and
requirements of The Nasdaq Global Market.
(c)
If an Investor Designee resigns from the Board, is removed, or
refuses or is unable to serve or fulfill his or her duties as a
director because of death or disability, in each case prior to the
expiration of the Director Period, the Investor shall have the
right to select a replacement Investor Designee, reasonably
acceptable to the Board and subject to compliance with the Director
Conditions, and shall provide the Company with the name of and
relevant background information for such replacement Investor
Designee. Subject to the terms of this Section 6, within twenty (20)
days following receipt of such information and compliance with the
Director Conditions, the Board will appoint such replacement
Investor Designee to the Board to replace the departing Investor
Designee to serve the remaining term of the departing Investor
Designee, and the replacement Investor Designee shall be considered
an Investor Designee for all purposes of this Section 6.
(d)
All confidential or proprietary information and data relating to
the Company and its Affiliates provided by the Company to the
Investor Designee shall be deemed confidential information and will
be kept confidential and not disclosed to any Person outside of the
Company. Notwithstanding the confidentiality obligations set forth
in Section
6(b)(iii) and the foregoing, and subject to Section 8.16, the Investor
Designee shall be permitted to disclose such confidential
information to the executive officers and members of the board of
directors (or equivalent governance body) of the Investor, its
shareholders and its advisers (such as legal counsel) having a duty
of confidentiality to the Investor, provided (i) such disclosure is
made on a need-to-know basis solely for the purposes of, and to the
extent necessary to, monitor and make decisions regarding the
Investor’s investment in the Company, and (ii) that the
Investor will be liable for any breach by any of such Persons of
the confidentiality obligations applicable to the Investor
Designee. Upon the resignation or removal of the Investor Designee
from the Board and written request (including via email) from the
Company, such Investor Designee shall either promptly (x) destroy
all confidential information of the Company that he or she received
in his or her capacity as a director in his or her possession or
control and any copies thereof or (y) return to the Company all
confidential information of the Company that he or she received in
his or her capacity as a director in his or her possession or
control and any copies thereof (but the Investor Designee need not
purge electronic archives and backups), and, in either case,
confirm in writing (which may be via email) to the Company that all
such material has been destroyed or returned, as applicable, in
compliance with this Section 6.
21
(e)
If any Investor Designee is an employee of, or otherwise
compensated by, the Investor or any of its Affiliates, such
Investor Designee shall not be entitled to any compensation from
the Company in connection with his or her role as a director or
service on the Board or any committee. The Investor Designee will
be entitled to reimbursement from the Company of out of pocket
expenses in connection with his or her role as a director
consistent with other directors on the Board.
(f)
Notwithstanding anything contained herein to the contrary, if the
Board (or any committee thereof) shall consider (i) a proposed
contract, transaction or other arrangement between the Investor or
any Investor Affiliate Assignee Parent (or any of their respective
Affiliates), on the one hand, and the Company or any of its
Affiliates, on the other hand, (ii) the enforcement or waiver of
the rights of the Company or any of its Affiliates under any
agreement between the Investor or any Investor Affiliate Assignee
Parent (or any of their respective Affiliates), on the one hand,
and the Company or any of its Affiliates, on the other hand, or
(iii) a matter which the Board determines in good faith presents an
actual or potential conflict of interest for the Investor Designee,
then the Investor Designee will, if directed by the chairperson of
the Board or the remaining directors, be excluded from
participation in such Board or committee meeting (or portion
thereof, as applicable) at which such matters are to be discussed,
and the Investor Designee will not be entitled to receive copies of
the materials or other documents relating to such matter or meeting
(or portion thereof, as applicable).
7. Subscription Right.
7.1
General. The
Company hereby grants to the Investor a subscription right (the
“Subscription
Right”) to purchase, following consummation of the
issuance of any New Securities by the Company after the Closing
Date (a “New Securities
Issuance”), such amount of the same type of New
Securities as those issued in such New Securities Issuance as
required to maintain its fully-diluted ownership as at immediately
prior to such New Securities Issuance, on the same terms and
conditions that are applicable to such New Securities in such New
Securities Issuance and at a price per share or security equal to
the price paid by the purchaser(s) in such New Securities Issuance
(“Additional Subscription
Shares”), provided that if the Company
issues shares of Common Stock or Common Stock Equivalents after the
Closing Date in a New Securities Issuance pursuant to the
acquisition of another Person by the Company by merger, purchase of
substantially all of the assets or other reorganization or to a
joint venture agreement and the Investor Designee does not approve
such acquisition (such issuance, a “Qualified Acquisition Issuance”),
then the Investor shall have the right to subscribe for Additional
Subscription Shares only by payment of cash consideration at the
Volume-Weighted Average Closing Price of the 30 consecutive Trading
Day period before the date of the announcement of such transaction
and on other terms to be mutually agreed between the Company and
the Investor; provided, further, that the Investor
shall have such Subscription Right only if the Investor
beneficially owns at least five percent (5.0%) of the shares of
Common Stock then issued and outstanding. For purposes of this
Section 7,
“fully-diluted
ownership” shall mean the issued and outstanding
Common Stock of the Company, assuming the conversion of all Common
Stock Equivalents.
22
7.2
Procedures. In the
event that the Company consummates a New Securities Issuance, it
shall provide the Investor with written notice of such New
Securities Issuance within 5 Business Days after the consummation
thereof (a “Subscription
Notice”), describing the amount and type of New
Securities, the identity of the purchaser(s) and the price and the
other material terms upon which the Company issued such New
Securities. The Investor shall have twenty (20) Business Days from
the date of receipt of the Subscription Notice to agree in writing
to purchase up to the Additional Subscription Shares by executing
the definitive purchase documentation on the same price, terms and
conditions as those applicable to such New Securities Issuance (in
the case of a New Securities Issuance that is not a Qualified
Acquisition Issuance), or by payment of cash consideration at the
Volume-Weighted Average Closing Price of the 30 consecutive Trading
Day period before the date of the announcement of the applicable
transaction and on other terms to be mutually agreed between the
Company and the Investor (in the case of a Qualified Acquisition
Issuance), provided
that under no circumstances shall this Section 7 entitle the Investor
to designate another member of the Board or, for the avoidance of
doubt, to enter into any new business relationship with the Company
or to have any rights against the Company other than as an investor
in the Company, provided, further, that, without
limitation to the Investor’s rights under Section 2, under no
circumstances shall the Company be required to register Additional
Subscription Shares under the Securities Act or qualify the
Additional Subscription Shares under the securities Laws of any
other jurisdiction in connection with the issuance thereof. If the
Investor fails to so respond in writing within such twenty (20)
Business Day period to purchase its Additional Subscription Shares,
then the Investor shall forfeit its Subscription Right hereunder
with respect to such New Securities Issuance. Notwithstanding the
foregoing, any consummation by the Investor of the Subscription
Right shall be subject to the satisfaction of all necessary Company
shareholder approval requirements and the obtainment of all
necessary consents, approvals and waivers under applicable
Law.
8. Miscellaneous.
8.1
Governing Law; Submission
to Jurisdiction. The law, including the statutes of
limitation, of the State of New York shall govern this Agreement,
the interpretation and enforcement of its terms and any claim or
cause of action (in law or equity), controversy or dispute arising
out of or related to it or its negotiation, execution or
performance, whether based on contract, tort, statutory or other
law, in each case without giving effect to any conflicts-of-law or
other principle requiring the application of the law of any other
jurisdiction.
8.2
Dispute Resolution.
The parties agree that any dispute or controversy arising out of,
relating to, or in connection with this Agreement or the
transactions contemplated hereby (a “Dispute”) shall be
arbitrated pursuant to the provisions of the Rules of Arbitration
of the International Chamber of Commerce (the “ICC Arbitration Rules”), by
three arbitrators (the “Tribunal”) appointed in
accordance with the ICC Arbitration Rules (the “Arbitration”). The
arbitration will be conducted in English, and shall take place in
San Francisco, California, or such other location as the parties
and the Tribunal may agree. The arbitral award (the “Award”) shall (a) be
rendered within 120 days after the Tribunal’s acceptance of
its appointment; (b) be delivered in writing; (c) state the reasons
for the Award; (d) be the sole and exclusive final and binding
remedy with respect to the Dispute between and among the parties
without the possibility of challenge or appeal, which are hereby
waived; and (e) be accompanied by a form of judgment. The Award
shall be deemed an award of the United States, the relationship
between the parties shall be deemed commercial in nature, and any
Dispute arbitrated pursuant to this Section 8.2 shall be deemed
commercial. The Tribunal shall have the authority to grant any
equitable or legal remedies, including entering preliminary or
permanent injunctive relief; provided, however, that the Tribunal
shall not have the authority to award (and the parties waive the
right to seek an award of) punitive or exemplary
damages.
23
8.3
Waiver. No failure
or delay of any party in exercising any right or remedy hereunder
shall operate as a waiver thereof, nor shall any single or partial
exercise of any such right or power, or any abandonment or
discontinuance of steps to enforce such right or power, or any
course of conduct, preclude any other or further exercise thereof
or the exercise of any other right or power. Any agreement on the
part of any party to any such waiver shall be valid only if set
forth in a written instrument executed and delivered by a duly
authorized officer on behalf of such party.
8.4
Notices. All
notices, instructions and other communications hereunder or in
connection herewith shall be in writing, shall be sent to the
address of the relevant party set forth on Exhibit A attached hereto and
shall be deemed duly given (a) on the date of delivery if delivered
personally, or if by facsimile or e mail, upon written confirmation
of receipt by facsimile, e-mail or otherwise, (b) on the first
Business Day following the date of dispatch if delivered utilizing
a next-day service by a recognized next-day courier or (c) on the
earlier of confirmed receipt or the fifth Business Day following
the date of mailing if delivered by registered or certified mail,
return receipt requested, postage prepaid. Any party may change its
address by giving notice to the other parties in the manner
provided above.
8.5
Entire Agreement.
This Agreement, the Purchase Agreement (once executed), the Joint
Venture Transaction Agreements (once executed) and the Warrants
(including all exhibits hereto and thereto) constitute the entire
agreement among the parties with respect to the subject matter
hereof and thereof and supersede all prior and contemporaneous
arrangements or understandings, whether written or oral, with
respect hereto and thereto.
8.6
Amendments. No
provision in this Agreement shall be modified or amended except in
a writing executed by an authorized representative of each of the
parties the Company and the Investor, and, in the case of
Section 5, by
the Founder.
8.7
Interpretation.
When a reference is made in this Agreement to a section,
subsection, article, exhibit or schedule such reference shall be to
a section, subsection, article, exhibit or schedule of this
Agreement unless otherwise indicated. The table of contents and
headings contained in this Agreement or in any exhibit or schedule
are for convenience of reference purposes only and shall not affect
in any way the meaning or interpretation of this Agreement. All
words used in this Agreement will be construed to be of such gender
or number as the circumstances require. Any capitalized terms used
in any exhibit or schedule but not otherwise defined therein shall
have the meaning as defined in this Agreement. All exhibits and
schedules annexed hereto or referred to herein are hereby
incorporated in and made a part of this Agreement as if set forth
herein. The word “including” and words of similar
import when used in this Agreement will mean “including,
without limitation,” unless otherwise specified. The words
“hereof,” “herein” and
“hereunder” and words of similar import when used in
this Agreement shall refer to this Agreement as a whole and not to
any particular provision in this Agreement. The term
“or” is not exclusive. The word “will”
shall be construed to have the same meaning and effect as the word
“shall.” References to days mean calendar days unless
otherwise specified. Whenever the context may require, any pronouns
used herein shall include the corresponding masculine, feminine or
neuter forms, and the singular form of names and pronouns shall
include the plural and vice-versa. This Agreement has been prepared
jointly and will not be construed against either
party.
24
8.8
Severability. If,
under applicable Laws, any provision hereof is invalid or
unenforceable, or otherwise directly or indirectly affects the
validity of any other material provision(s) of this Agreement in
any jurisdiction (“Modified
Clause”), then, it is mutually agreed that this
Agreement shall endure and that the Modified Clause shall be
enforced in such jurisdiction to the maximum extent permitted under
applicable Laws in such jurisdiction; provided that the parties shall
consult and use all reasonable best efforts to agree upon, and
hereby consent to, any valid and enforceable modification of this
Agreement as may be necessary to avoid any unjust enrichment of
either party and to match the intent of this Agreement as closely
as possible, including the economic benefits and rights
contemplated herein.
8.9
Assignment. Neither
this Agreement nor any of the rights or obligations hereunder may
be assigned by the Investor or the Company without (a) the prior
written consent of the Company in the case of any assignment by the
Investor or (b) the prior written consent of the Investor in the
case of an assignment by the Company or the Founder; provided that no such consent
shall be required from the Investor in connection with any
acquisition of the Company or a majority of the outstanding shares
of Common Stock, in each case in a single or series of related
transactions. Notwithstanding anything to the contrary, SK global
chemical Co., Ltd. may assign its rights and obligations as
Investor under this Agreement and the Purchase Agreement to any of
its Affiliates in which it directly owns a majority of the total
voting power represented by all shares of capital stock and any
other voting securities of such Affiliate (an “Investor Affiliate Assignee”) from
time to time without the consent of the Company or the Founder,
provided that (i)
the Investor Affiliate Assignee shall be deemed to be the
“Investor” for purposes of this Agreement and the
Purchase Agreement, and shall be entitled to all rights, and shall
be subject to all obligations, of the Investor hereunder and
thereunder, (ii) each of the Investor Affiliate Assignee’s
most immediate owners that are listed on xxx.xx.xxx/xxxxxxxxx
(excluding any subsidiaries of any Persons listed thereon) (each an
“Investor Affiliate Assignee
Parent”) executes and delivers to the Company a
joinder in such form that is reasonably satisfactory to the Company
under which such Investor Affiliate Assignee Parent acknowledges
and agrees to be bound by all provisions applicable to an Investor
Affiliate Assignee Parent under this Agreement and under the
Purchase Agreement (an “Investor Affiliate Assignee
Joinder”), provided that an Investor
Affiliate Assignee Parent that (A) owns less than 10% of the voting
securities of the Investor Affiliate Assignee (measured by voting
power) and (B) does not otherwise control the power to vote 10% or
greater of the voting securities of the Investor Affiliate Assignee
or otherwise have the right to direct the management or policies of
the Investor Affiliate Assignee shall not be required to execute an
Investor Affiliate Assignee Joinder, (iii) SK global chemical Co.,
Ltd. shall be, upon such assignment, subject to all provisions
applicable to, and shall be deemed, an Investor Affiliate Assignee
Parent under this Agreement and under the Purchase Agreement, and
(iv) SK global chemical Co., Ltd. shall remain bound by all
obligations of the Investor under this Agreement and under the
Purchase Agreement, unless SK global chemical Co., Ltd. provides
guarantees in such form that is reasonably satisfactory to the
Company from such other Investor Affiliate Assignee Parents that
have (1) substantially the same creditworthiness as SK global
chemical Co., Ltd. (as determined in the reasonable discretion of
the Company) and (2) have executed and delivered to the Company
Investor Affiliate Assignee Joinders, under which each such
Investor Affiliate Assignee Parent unconditionally and irrevocably
guarantees to the Company the full and punctual performance of and
compliance with all covenants, agreements and other obligations of
the Investor, now or hereafter existing, under this Agreement or
the Purchase Agreement, provided that (x) such
guarantee may be made on a several but not joint basis by each
Investor Affiliate Assignee Parent executing such guarantee,
provided,
further, that under
no circumstances shall the Investor Affiliate Assignee Parents
executing such guarantee in accordance with this Section 8.9, together with
SK global chemical Co., Ltd., be liable in the aggregate for less
than all of the Investor’s obligations hereunder and (y) upon
any breach or default by the Investor, the Company shall not be
obligated to first attempt enforcement against the Investor under
such guarantee (such assignment, an “Investor Permitted
Assignment”).
25
8.10
Successors and
Assigns. The terms and conditions of this Agreement shall
inure to the benefit of, and shall be binding upon, the respective
successors and permitted assignees of the parties.
8.11
Counterparts. This
Agreement may be executed in two or more counterparts, and by
facsimile, pdf or other electronic format, each of which shall be
deemed an original, and all of which together shall constitute one
and the same instrument.
8.12
Fees and Expenses.
Except as otherwise provided herein and therein, all fees and
expenses incurred in connection with or related to this Agreement
and the other Transaction Agreements and the transactions
contemplated hereby and thereby shall be paid by the party
incurring such fees or expenses, whether or not such transactions
are consummated.
8.13
Third Party
Beneficiaries. None of the provisions of this Agreement
shall be for the benefit of or enforceable by any Third Party,
including any creditor of any party hereto. No Third Party shall
obtain any right under any provision of this Agreement or shall by
reason of any such provision make any claim in respect of any debt,
liability or obligation (or otherwise) against any party
hereto.
8.14
Remedies. The
rights, powers and remedies of the parties under this Agreement are
cumulative and not exclusive of any other right, power or remedy
which such parties may have under any other agreement or Law. No
single or partial assertion or exercise of any right, power or
remedy of a party hereunder shall preclude any other or further
assertion or exercise thereof.
8.15
Specific
Performance. The parties hereby acknowledge and agree that
the rights of the parties hereunder are special, unique and of
extraordinary character, and that if any party refuses or otherwise
fails to act, or to cause, direct or request its Affiliates to act,
in accordance with the provisions of this Agreement, such refusal
or failure would result in irreparable injury to the Company, the
Investor or the Founder as the case may be, the exact amount of
which would be difficult to ascertain or estimate and the remedies
at law for which would not be reasonable or adequate compensation.
Accordingly, if any party refuses or otherwise fails to act, or to
cause its Affiliates to act, in accordance with the provisions of
this Agreement, then, in addition to any other remedy which may be
available to any damaged party at law or in equity, such damaged
party will be entitled to obtain specific performance and
injunctive relief, without posting bond or other security, and
without the necessity of proving actual or threatened damages,
which remedy such damaged party will be entitled to seek in any
court of competent jurisdiction. Each party hereto hereby further
waives any defense in any action for specific performance that a
remedy at law would be adequate.
26
8.16
Confidentiality.
The Investor and each Investor Affiliate Assignee Parent shall, and
shall cause their respective Affiliates and Representatives to,
keep confidential any information (including oral, written and
electronic information) concerning the Company, its subsidiaries or
its Affiliates that may be furnished to the Investor, any Investor
Affiliate Assignee Parent or their respective Affiliates or
Representatives by or on behalf of the Company or any of its
Representatives pursuant to this Agreement (the “Confidential Information”) and to
use the Confidential Information solely in connection with the
Investor’s investment in the Company; provided that the Confidential
Information will not include information that (a) is, was or
becomes available to the public (other than as a result of a breach
of any confidentiality obligation by the Investor, any Investor
Affiliate Assignee Parent or their respective Affiliates), (b) is
or has been independently developed or conceived by the Investor,
any Investor Affiliate Assignee Parent or their respective
Affiliates without use of the Confidential Information or (c) is or
has been made known or disclosed to the Investor, any Investor
Affiliate Assignee Parent or their respective Affiliates by a Third
Party without a breach of any confidentiality obligations such
Third Party has to the Company that is known to the Investor, any
Investor Affiliate Assignee Parent or their respective Affiliates;
provided further
that, the Investor may disclose the Confidential Information (i) to
its Representatives in connection with its investment in the
Company, (ii) to any prospective purchaser of any shares of Common
Stock from the Investor and their respective Representatives,
provided that (A)
to the knowledge of the Investor upon reasonable inquiry, such
prospective purchaser is not a Competitor or otherwise a party to
whom the Investor is not permitted to transfer Common Stock
pursuant to Section
4.3 of this Agreement, (B) such prospective purchaser agrees
to be bound by a confidentiality or non-disclosure agreement with
the Investor that is no less restrictive than the confidentiality
obligations set forth herein, as the case may be, and agrees to
bind each of its Representatives who receives any Confidential
Information to also be subject to confidentiality or non-disclosure
agreements that are no less restrictive than the confidentiality
obligations set forth herein, and (C) within seven (7) days of
providing any Confidential Information to any such prospective
purchaser, the Investor provides notice to the Company identifying
such prospective purchaser, (iii) to any Investor Affiliates and
their respective Representatives, in each case in the ordinary
course of business (provided that the recipients of
such Confidential Information are subject to a confidentiality and
non-disclosure obligation no less restrictive than the
confidentiality obligations set forth herein), or (iv) as may
otherwise be required by law or legal, judicial or regulatory
process, provided
that (x) the Investor provides prompt prior written notice to the
Company notifying the Company of the manner, scope and
justification for such disclosure, (y) the Investor takes
reasonable steps to minimize the extent of any required disclosure
described in this clause (iv) and (z) such disclosure requirement
does not arise from a breach of Section 3 of this
Agreement; and provided, further, that the acts and
omissions of any Person to whom the Investor may disclose the
Confidential Information (and such Person’s Representatives
who receive any such Confidential Information) pursuant to clauses
(i), (ii) and (iii) of the preceding proviso shall be attributable
to the Investor for purposes of determining the Investor’s
compliance with this Section 8.16, except those who
have entered into a separate confidentiality or non-disclosure
agreement, or are subject to a separate confidentiality or
non-disclosure obligation, with the Company. Notwithstanding
anything to the contrary set forth herein or set forth in the
Purchase Agreement, under no circumstances shall the Investor or an
Investor Affiliate Assignee Parent that has executed and delivered
to the Company an Investor Affiliate Assignee Joinder disclose any
Confidential Information (as defined herein and as defined under
the Purchase Agreement) to any Person that owns any shares of
Investor that is not an Investor Affiliate Assignee Parent and has
not executed and delivered to the Company an Investor Affiliate
Assignee Joinder (each an “Investor Affiliate Holder”),
except for such disclosures either (1) made with the prior written
consent of the Company or (2) made to such Investor Affiliate
Holders that have entered into a separate confidentiality or
non-disclosure agreement with the Company. Any Investor Permitted
Assignment shall be deemed to exclude the right of an Investor
Affiliate Holder to accessing such Confidential
Information.
8.17
Termination. Any of
Investor’s or Investor Affiliate Assignee Parent’s
obligations set forth in this Agreement shall terminate once such
Person no longer holds, directly or indirectly, any equity interest
or voting power in the Company.
(Signature
Page Follows)
27
IN
WITNESS WHEREOF, the parties have executed and delivered this
Agreement as of the date first above written.
|
By:
__________________________________
Name:
Title:
FOUNDER:
__________________________________
Xxxxxx
Xxxxxxxx
Solely
for purposes of Section 5
|
IN
WITNESS WHEREOF, the parties have executed and delivered this
Agreement as of the date first above written.
|
SK
GLOBAL CHEMICAL CO., LTD.
By:
_______________________________
Name:
Title:
|
EXHIBIT A
NOTICE ADDRESSES